Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Molecular Pharmaceutics|March 28, 2023
Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in MiceNancy H C Loos, Margarida L F Martins, Daniëlle de Jong, et al.
International Journal of Pharmaceutics|December 22, 2023
Coadministration of ABCB1/P-glycoprotein inhibitor elacridar improves tissue distribution of ritonavir-boosted oral cabazitaxel in miceNancy H C Loos, Margarida L F Martins, Daniëlle de Jong, et al.
Annales De Dermatologie Et De Venereologie|September 25, 1998
[Pruritus and the hepatitis C virus. The MULTIVIRC Unit]H Dega, C Francès, N Dupin, et al.
Molecular Pharmaceutics|February 29, 2024
Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in MiceNancy H C Loos, Margarida L Ferreira Martins, Jamie Rijmers, et al.
Arthritis Research & Therapy|December 10, 2013
FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritisMaria I Ramos, Samuel Garcia Perez, Saida Aarrass, et al.
Molecular Cancer Therapeutics|March 31, 2021
ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor SelitrectinibWenlong Li, Rolf W Sparidans, Margarida L F Martins, et al.
Toxicology and Applied Pharmacology|July 20, 2024
The role of drug efflux and uptake transporters in the plasma pharmacokinetics and tissue disposition of morphine and its main metabolitesMargarida L F Martins, Paniz Heydari, Wenlong Li, et al.
Pageof 6